TABLE 40Health-state utilities

Health stateUtility
SVR (from mild disease)0.82
SVR (from moderate disease)0.72
Mild HCV0.77
Treatment for mild HCV0.66
Moderate HCV0.66
Treatment for moderate HCV0.55
Cirrhosis0.55
DC0.45
HCC0.45
LT0.45
Post LT0.67

DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplantation; post LT, post liver transplantation.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
Southampton (UK): NIHR Journals Library; 2011 Apr.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.